RP910

RP910 is a small interfering RNA (siRNA) therapeutic designed to target and inhibit the production of **proprotein convertase subtilisin/kexin type 9 (PCSK9)**. Developed through a collaboration between **Risen Shanghai Medical Technology** (also known as Risen Suzhou Pharma Technology) and **TopAlliance**, the drug utilizes a proprietary **GalNAc (N-acetylgalactosamine)** delivery system to facilitate specific uptake by hepatocytes. By silencing the PCSK9 gene, RP910 reduces the circulating levels of the PCSK9 protein, which normally promotes the degradation of LDL receptors. This reduction leads to an increase in LDL receptor density on the surface of liver cells, thereby enhancing the clearance of LDL cholesterol from the blood. RP910 is primarily indicated for the treatment of **dyslipidemia** and the prevention of associated **cardiovascular diseases**.